AbCellera Biologics Inc. (FRA:8QQ)

Germany · Delayed Price · Currency is EUR

2.600

-0.200 (-7.14%)

Last updated: Feb 23, 2026, 8:12 AM CET

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Discovery and Development of Antibodies	28.83M	38.03M	485.42M	375.20M	233.16M
Discovery and Development of Antibodies Growth	-24.17%	-92.17%	29.38%	60.92%	1907.88%
Total	28.83M	38.03M	485.42M	375.20M	233.16M
Total Growth	-24.17%	-92.17%	29.38%	60.92%	1907.88%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Canada	28.83M	38.03M	485.42M	375.20M	233.16M
Canada Growth	-24.17%	-92.17%	29.38%	60.92%	1907.88%
Total	28.83M	38.03M	485.42M	375.20M	233.16M
Total Growth	-24.17%	-92.17%	29.38%	60.92%	1907.88%

Source: S&P Global Market Intelligence.